Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies

NCT00504972 is registered in ClinicalTrials.gov with Weill Medical College of Cornell University as lead sponsor.

NCT NCT00504972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00504972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies
Lead sponsor
Weill Medical College of Cornell University
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2007
Completion date
October 7, 2015
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, non-hodgkin's lymphoma